IL154685A0
(en)
*
|
2000-10-20 |
2003-09-17 |
Biovitrum Ab |
2-,3-,4-, or 5-substituted-n1-(benzensulfonyl) indoles and their use in therapy
|
GB0112497D0
(en)
*
|
2001-05-22 |
2001-07-11 |
Smithkline Beecham Plc |
Formulation
|
GB0206200D0
(en)
*
|
2002-03-15 |
2002-05-01 |
Glaxo Group Ltd |
Pharmaceutical compositions
|
GB0209022D0
(en)
|
2002-04-19 |
2002-05-29 |
Imp College Innovations Ltd |
Compounds
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
US7140567B1
(en)
*
|
2003-03-11 |
2006-11-28 |
Primet Precision Materials, Inc. |
Multi-carbide material manufacture and use as grinding media
|
DK1651401T3
(da)
|
2003-06-17 |
2009-09-14 |
Phibrowood Llc |
Partikelformigt trækonserveringsmiddel og fremgangsmåde til fremstilling deraf
|
GB0320522D0
(en)
*
|
2003-09-02 |
2003-10-01 |
Glaxo Group Ltd |
Formulation
|
WO2005023257A1
(en)
|
2003-09-03 |
2005-03-17 |
Glaxo Group Limited |
Novel process, salts, compositions and use
|
US20050252408A1
(en)
*
|
2004-05-17 |
2005-11-17 |
Richardson H W |
Particulate wood preservative and method for producing same
|
US7578455B2
(en)
*
|
2004-08-09 |
2009-08-25 |
General Motors Corporation |
Method of grinding particulate material
|
NZ554680A
(en)
|
2004-10-14 |
2010-10-29 |
Osmose Inc |
Micronized wood preservative formulations in organic carriers
|
WO2006062238A1
(ja)
*
|
2004-12-07 |
2006-06-15 |
Ajinomoto Co., Inc. |
アミノ酸の微粉末及びその懸濁液
|
WO2006091885A2
(en)
|
2005-02-24 |
2006-08-31 |
Dr Pharma Nova, Llc |
A registry method and control system for dea schedule ii-v medicines
|
PL2559690T3
(pl)
|
2005-05-10 |
2016-09-30 |
|
Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
|
JP2008540503A
(ja)
|
2005-05-10 |
2008-11-20 |
グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ |
細菌感染症の処置に有用なエーテル結合マクロライド
|
CA2621261C
(en)
|
2005-09-22 |
2014-05-20 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
PL2474545T3
(pl)
|
2005-12-13 |
2017-04-28 |
Incyte Holdings Corporation |
Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej
|
WO2007075598A2
(en)
|
2005-12-20 |
2007-07-05 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
GB0600928D0
(en)
|
2006-01-17 |
2006-02-22 |
Novacta Biosystems Ltd |
Improvements relating to lantibiotics
|
DE102006028590A1
(de)
*
|
2006-06-22 |
2007-12-27 |
Forschungszentrum Karlsruhe Gmbh |
Vorrichtung und Verfahren zur Herstellung keramischer Granulate
|
JP5274455B2
(ja)
|
2006-06-23 |
2013-08-28 |
インサイト コーポレイション |
Hm74aアゴニストとしてのプリノン誘導体
|
TWI423977B
(zh)
|
2006-06-23 |
2014-01-21 |
Incyte Corp |
作為hm74a同效劑之嘌呤酮衍生物(一)
|
US7828543B2
(en)
*
|
2006-07-27 |
2010-11-09 |
Casa Herrera, Inc. |
Dough sheeter cutter roller
|
CA2660836A1
(en)
|
2006-08-07 |
2008-02-21 |
Incyte Corporation |
Triazolotriazines as kinase inhibitors
|
EP2061459B1
(en)
|
2006-08-23 |
2012-12-26 |
Intellect Neurosciences Inc. |
3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
EP2064207B1
(en)
|
2006-09-19 |
2013-11-06 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
US8513270B2
(en)
|
2006-12-22 |
2013-08-20 |
Incyte Corporation |
Substituted heterocycles as Janus kinase inhibitors
|
US7883039B2
(en)
*
|
2007-02-27 |
2011-02-08 |
Collette Nv |
Continuous granulating and drying apparatus including measurement units
|
JP2008235481A
(ja)
*
|
2007-03-19 |
2008-10-02 |
Nippon Chem Ind Co Ltd |
半導体ウエハ研磨用組成物、その製造方法、及び研磨加工方法
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
HUE043732T2
(hu)
|
2007-06-13 |
2019-09-30 |
Incyte Holdings Corp |
Januskináz gátló hatású (R)-3-(4-(7H pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropánnitril sók alkalmazása
|
CL2008001839A1
(es)
|
2007-06-21 |
2009-01-16 |
Incyte Holdings Corp |
Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
|
GB0714029D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
Lantibiotic-based compounds having antimicrobial activity
|
GB0714030D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
The use of type-B lantibiotic-based compounds having antimicrobial activity
|
ES2380165T3
(es)
|
2007-08-02 |
2012-05-09 |
Recordati Ireland Limited |
Nuevos compuestos heterocíclicos como antagonistas mGlu5
|
ES2569528T3
(es)
|
2007-11-16 |
2016-05-11 |
Incyte Holdings Corporation |
4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus
|
AU2009223640B2
(en)
|
2008-03-11 |
2013-07-04 |
Incyte Holdings Corporation |
Azetidine and cyclobutane derivatives as jak inhibitors
|
JP2011518836A
(ja)
|
2008-04-24 |
2011-06-30 |
インサイト・コーポレイション |
大環状化合物およびそれらのキナーゼ阻害剤としての使用
|
NZ589622A
(en)
|
2008-05-21 |
2012-10-26 |
Incyte Corp |
Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
|
DK2824100T3
(en)
|
2008-07-08 |
2018-04-16 |
Incyte Holdings Corp |
1,2,5-oxadiazoles as inhibitors of indolamine-2,3-dioxygenase
|
WO2010077839A1
(en)
|
2008-12-15 |
2010-07-08 |
Wyeth Llc (Formerly Known As Wyeth) |
Substituted oxindol cb2 agonists for pain treatment
|
WO2010090680A1
(en)
|
2008-12-15 |
2010-08-12 |
Wyeth Llc |
Substituted oxindole cb2 agonists
|
TW201024277A
(en)
|
2008-12-22 |
2010-07-01 |
Incyte Corp |
Substituted heterocyclic compounds
|
GB0900599D0
(en)
|
2009-01-14 |
2009-02-18 |
Novacta Biosystems Ltd |
Treatment
|
JP5719312B2
(ja)
|
2009-01-14 |
2015-05-13 |
ノヴァクタ バイオシステムズ リミティッド |
デオキシアクタガルジン誘導体
|
US8765727B2
(en)
|
2009-01-23 |
2014-07-01 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
SG173158A1
(en)
*
|
2009-01-30 |
2011-08-29 |
Meiji Seika Pharma Co Ltd |
Finely pulverized pharmaceutical composition
|
NZ594675A
(en)
|
2009-02-04 |
2013-11-29 |
Novacta Biosystems Ltd |
Actagardine derivatives
|
US20100317630A1
(en)
|
2009-02-04 |
2010-12-16 |
Recordati Ireland Limited |
Novel heterocyclic compounds as mglu5 antagonists
|
CA2752150A1
(en)
|
2009-02-11 |
2010-08-19 |
Reaction Biology Corp. |
Selective kinase inhibitors
|
US20100227921A1
(en)
|
2009-03-03 |
2010-09-09 |
Shire Llc |
Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
|
WO2010108059A1
(en)
|
2009-03-20 |
2010-09-23 |
Incyte Corporation |
Substituted pyrimidine derivatives as antagonists of the histamine h4 receptor
|
MX2011010448A
(es)
|
2009-04-02 |
2011-10-28 |
Shire Llc |
Profarmacos de opioides novedosos de amino acidos y peptidos enlazados a acido dicarboxilico y usos de los mismos.
|
AU2010249380B2
(en)
|
2009-05-22 |
2015-08-20 |
Incyte Holdings Corporation |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
|
CA2761954C
(en)
|
2009-05-22 |
2018-07-31 |
Incyte Corporation |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
WO2010149760A2
(en)
|
2009-06-24 |
2010-12-29 |
Shire Llc |
Mexiletine amino acid and peptide prodrugs and uses thereof
|
CA2766100C
(en)
|
2009-06-29 |
2018-05-22 |
Incyte Corporation |
Pyrimidinones as pi3k inhibitors
|
JP2013527124A
(ja)
|
2009-07-17 |
2013-06-27 |
シャイア エルエルシー |
オピオイドの新規カルバマートアミノ酸およびペプチドプロドラッグならびにその使用
|
EP2456434A1
(en)
|
2009-07-23 |
2012-05-30 |
Shire LLC |
Galantamine amino acid and peptide prodrugs and uses thereof
|
WO2011022393A2
(en)
|
2009-08-17 |
2011-02-24 |
The Brigham And Women's Hospital, Inc. |
Phosphatidylcholine transfer protein inhibitors
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
EP2477981A1
(en)
|
2009-09-14 |
2012-07-25 |
Recordati Ireland Limited |
Heterocyclic mglu5 antagonists
|
GB0916163D0
(en)
|
2009-09-15 |
2009-10-28 |
Shire Llc |
Prodrugs of guanfacine
|
CN102596960B
(zh)
|
2009-10-09 |
2016-01-20 |
因西特控股公司 |
3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
TW201130842A
(en)
|
2009-12-18 |
2011-09-16 |
Incyte Corp |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
WO2011083304A1
(en)
|
2010-01-05 |
2011-07-14 |
Shire Llc |
Prodrugs of opioids and uses thereof
|
GB201001688D0
(en)
|
2010-02-02 |
2010-03-17 |
Novacta Biosystems Ltd |
Compounds
|
MX2012008819A
(es)
|
2010-02-02 |
2012-09-28 |
Novacta Biosystems Ltd |
Sales de lantibioticos.
|
EA023444B1
(ru)
|
2010-02-18 |
2016-06-30 |
Инсайт Холдингс Корпорейшн |
Циклобутановые и метилциклобутановые производные, композиции на их основе и способы их применения
|
AR081315A1
(es)
|
2010-03-10 |
2012-08-08 |
Incyte Corp |
Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t
|
EP2558463A1
(en)
|
2010-04-14 |
2013-02-20 |
Incyte Corporation |
Fused derivatives as i3 inhibitors
|
NZ603686A
(en)
|
2010-05-21 |
2014-11-28 |
Incyte Corp |
Topical formulation for a jak inhibitor
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
JP2013529673A
(ja)
|
2010-07-09 |
2013-07-22 |
レコルダーティ アイルランド リミテッド |
Mglu5アンタゴニストとしての新規スピロ複素環化合物
|
GB201013507D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013513D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Formulations
|
GB201013509D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013508D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
EP2609105B1
(en)
|
2010-08-24 |
2016-03-09 |
Imperial Innovations Limited |
Glycodendrimers of polypropyletherimine
|
ES2524892T3
(es)
|
2010-09-02 |
2014-12-15 |
Glaxosmithkline Intellectual Property Development Limited |
2-(Benciloxi)benzamidas como inhibidores de LRRK2 quinasa
|
CA2812029A1
(en)
|
2010-09-15 |
2012-03-22 |
Shire Llc |
Prodrugs of guanfacine
|
WO2012046062A1
(en)
|
2010-10-05 |
2012-04-12 |
Shire, Llc |
Use of prodrugs to avoid gi mediated adverse events
|
JP2014504260A
(ja)
*
|
2010-10-15 |
2014-02-20 |
グラクソ グループ リミテッド |
集合ナノ粒子状薬物製剤、その製造及び使用
|
EA026201B1
(ru)
|
2010-11-19 |
2017-03-31 |
Инсайт Холдингс Корпорейшн |
Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
|
JP5917544B2
(ja)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
|
TW201249844A
(en)
|
2010-12-20 |
2012-12-16 |
Incyte Corp |
N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
|
US20120196933A1
(en)
|
2010-12-23 |
2012-08-02 |
Richard Franklin |
Mexiletine prodrugs
|
EP3042654A1
(en)
|
2011-01-20 |
2016-07-13 |
Bionevia Pharmaceuticals Inc. |
Modified release compositions of epalrestat or a derivative thereof and methods for using the same
|
US9499462B2
(en)
|
2011-02-02 |
2016-11-22 |
Cognition Therapeutics, Inc. |
Isolated compounds from turmeric oil and methods of use
|
WO2012112440A2
(en)
|
2011-02-14 |
2012-08-23 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University |
Fluorescent potassium ion sensors
|
PL2675451T3
(pl)
|
2011-02-18 |
2016-05-31 |
Novartis Pharma Ag |
Terapia skojarzona z inhibitorem mTOR/JAK
|
TW201241005A
(en)
|
2011-02-18 |
2012-10-16 |
Alexion Pharma Inc |
Methods for synthesizing molybdopterin precursor Z derivatives
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
AR086983A1
(es)
|
2011-06-20 |
2014-02-05 |
Incyte Corp |
Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
|
US9180099B2
(en)
|
2011-07-07 |
2015-11-10 |
Arqule Inc. |
Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
|
WO2013023119A1
(en)
|
2011-08-10 |
2013-02-14 |
Novartis Pharma Ag |
JAK P13K/mTOR COMBINATION THERAPY
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
IL299533A
(en)
|
2011-09-02 |
2023-02-01 |
Incyte Holdings Corp |
Heterocycloamines as P13K inhibitors
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
JP6073545B2
(ja)
*
|
2011-10-04 |
2017-02-01 |
横浜油脂工業株式会社 |
リグナン類含有微粒子及び組成物
|
US8895571B2
(en)
|
2011-10-14 |
2014-11-25 |
Incyte Corporation |
Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
BR112014025518B1
(pt)
|
2012-04-13 |
2022-05-24 |
Glaxosmithkline Intellectual Property Development Limited |
Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas
|
AR091079A1
(es)
|
2012-05-18 |
2014-12-30 |
Incyte Corp |
Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
|
DK3176170T3
(en)
|
2012-06-13 |
2019-01-28 |
Incyte Holdings Corp |
SUBSTITUTED TRICYCLIC RELATIONS AS FGFR INHIBITORS
|
EP2890379B1
(en)
|
2012-08-29 |
2019-04-03 |
Icahn School of Medicine at Mount Sinai |
Benzothiazole or benzoxazole compounds as sumo activators
|
EP2906564B1
(en)
|
2012-10-12 |
2018-08-22 |
Mayo Foundation For Medical Education And Research |
Treating brain cancer using agelastatin a (aa) and analogues thereof
|
EA031882B1
(ru)
|
2012-11-01 |
2019-03-29 |
Инсайт Холдингс Корпорейшн |
Трициклические конденсированные производные тиофена как ингибиторы jak
|
PL2919766T3
(pl)
|
2012-11-15 |
2021-10-04 |
Incyte Holdings Corporation |
Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
|
US9504691B2
(en)
*
|
2012-12-06 |
2016-11-29 |
Alcon Research, Ltd. |
Finafloxacin suspension compositions
|
JP6437452B2
(ja)
|
2013-01-14 |
2018-12-12 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
|
DK2945939T3
(da)
|
2013-01-15 |
2020-03-23 |
Incyte Holdings Corp |
Thiazolcarboxamider og pyridincarboxamidforbindelser anvendelige som pim-kinaseinhibitorer
|
CN105121023B
(zh)
*
|
2013-02-28 |
2017-08-25 |
太阳化学公司 |
用于在液体分散液中制造研磨的固体的装置和连续方法
|
TWI687220B
(zh)
|
2013-03-01 |
2020-03-11 |
美商英塞特控股公司 |
吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
|
AU2014225938B2
(en)
|
2013-03-06 |
2018-07-19 |
Incyte Holdings Corporation |
Processes and intermediates for making a JAK inhibitor
|
US9815847B2
(en)
|
2013-03-14 |
2017-11-14 |
Icahn School Of Medicine At Mount Sinai |
Pyrimidine compounds as kinase inhibitors
|
EP3581576B1
(en)
|
2013-03-15 |
2022-01-26 |
Incyte Holdings Corporation |
Tricyclic heterocycles as bet protein inhibitors for use in the treatment of a proliferative disease in combination with a janus kinase inhibitor
|
ES2893725T3
(es)
|
2013-04-19 |
2022-02-09 |
Incyte Holdings Corp |
Heterocíclicos bicíclicos como inhibidores del FGFR
|
FI3786162T3
(fi)
|
2013-05-17 |
2023-10-02 |
Incyte Holdings Corp |
Bipyratsolijohdannaisia jak-inhibiittoreina
|
JP2016523964A
(ja)
|
2013-07-08 |
2016-08-12 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Betタンパク質阻害剤としての三環式複素環
|
MX2016001639A
(es)
|
2013-08-07 |
2016-10-07 |
Incyte Corp |
Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
|
AR097431A1
(es)
|
2013-08-23 |
2016-03-16 |
Incyte Corp |
Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
|
HUE049337T2
(hu)
|
2013-11-08 |
2020-09-28 |
Incyte Holdings Corp |
Eljárás indolamin-2,3-dioxigenáz inhibitor elõállítására
|
WO2015071841A1
(en)
|
2013-11-12 |
2015-05-21 |
Druggability Technologies Holdings Limited |
Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
|
WO2015081246A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
US9315501B2
(en)
|
2013-11-26 |
2016-04-19 |
Incyte Corporation |
Bicyclic heterocycles as BET protein inhibitors
|
WO2015081203A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
WO2015095492A1
(en)
|
2013-12-19 |
2015-06-25 |
Incyte Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
EP3626707A1
(en)
|
2014-01-13 |
2020-03-25 |
The General Hospital Corporation |
Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin
|
EP4023294A1
(en)
|
2014-01-31 |
2022-07-06 |
Cognition Therapeutics, Inc. |
Isoindoline compositions and methods for treating alzheimer's disease
|
EP3392244A1
(en)
|
2014-02-13 |
2018-10-24 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
WO2015123437A1
(en)
|
2014-02-13 |
2015-08-20 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
HUE045725T2
(hu)
|
2014-02-13 |
2020-01-28 |
Incyte Corp |
Ciklopropilaminok mint LSD1 inhibitorok
|
LT3105218T
(lt)
|
2014-02-13 |
2019-12-10 |
Incyte Corp |
Ciklopropilaminai kaip lsd1 inhibitoriai
|
HUE041456T2
(hu)
|
2014-02-28 |
2019-05-28 |
Incyte Corp |
JAK1 inhibitorok myelodysplasiás szindrómák kezelésére
|
MA39984B1
(fr)
|
2014-04-08 |
2020-12-31 |
Incyte Corp |
Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné
|
CA2946731C
(en)
|
2014-04-23 |
2022-06-07 |
Incyte Corporation |
1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
|
EA201692193A1
(ru)
|
2014-04-30 |
2017-07-31 |
Инсайт Корпорейшн |
Способы получения ингибитора jak1 и его новых форм
|
TW201625641A
(zh)
|
2014-05-22 |
2016-07-16 |
健臻公司 |
Nampt抑制劑及方法
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
WO2015188015A1
(en)
|
2014-06-04 |
2015-12-10 |
Haro Pharmaceutical Inc. |
18-20 member bi-polycyclic compounds
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
US9695167B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
|
US9758523B2
(en)
|
2014-07-10 |
2017-09-12 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as LSD1 inhibitors
|
WO2016007731A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Imidazopyridines and imidazopyrazines as lsd1 inhibitors
|
TW201613925A
(en)
|
2014-07-10 |
2016-04-16 |
Incyte Corp |
Imidazopyrazines as LSD1 inhibitors
|
WO2016010897A1
(en)
|
2014-07-14 |
2016-01-21 |
Incyte Corporation |
Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
|
US9580418B2
(en)
|
2014-07-14 |
2017-02-28 |
Incyte Corporation |
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
|
ES2855225T3
(es)
|
2014-09-15 |
2021-09-23 |
Incyte Corp |
Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
|
CN107206000A
(zh)
|
2014-12-22 |
2017-09-26 |
阿鲁兹特拉生物有限公司 |
预防和治疗血小板增多的癌症患者中的转移性疾病
|
CN107406461B
(zh)
|
2014-12-29 |
2020-03-13 |
雷科尔达蒂爱尔兰有限公司 |
杂环炔烃衍生物及其作为mGluR5受体调节剂的用途
|
US9586949B2
(en)
|
2015-02-09 |
2017-03-07 |
Incyte Corporation |
Aza-heteroaryl compounds as PI3K-gamma inhibitors
|
CN107438607B
(zh)
|
2015-02-20 |
2021-02-05 |
因赛特公司 |
作为fgfr抑制剂的双环杂环
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
HUE060953T2
(hu)
|
2015-02-27 |
2023-04-28 |
Incyte Holdings Corp |
Eljárások PI3K inhibitor elõállítására
|
MA51438A
(fr)
|
2015-04-03 |
2021-04-14 |
Incyte Corp |
Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
US20160362424A1
(en)
|
2015-05-11 |
2016-12-15 |
Incyte Corporation |
Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
|
WO2016196244A1
(en)
|
2015-05-29 |
2016-12-08 |
Incyte Corporation |
Pyridineamine compounds useful as pim kinase inhibitors
|
WO2016193900A1
(en)
*
|
2015-06-05 |
2016-12-08 |
Lupin Limited |
Compositions of diclofenac acid
|
MX2018001706A
(es)
|
2015-08-12 |
2018-09-06 |
Incyte Corp |
Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
|
WO2017035366A1
(en)
|
2015-08-26 |
2017-03-02 |
Incyte Corporation |
Pyrrolopyrimidine derivatives as tam inhibitors
|
AR105967A1
(es)
|
2015-09-09 |
2017-11-29 |
Incyte Corp |
Sales de un inhibidor de pim quinasa
|
EP3353156B1
(en)
|
2015-09-23 |
2021-11-03 |
The General Hospital Corporation |
Tead transcription factor autopalmitoylation inhibitors
|
US9920032B2
(en)
|
2015-10-02 |
2018-03-20 |
Incyte Corporation |
Heterocyclic compounds useful as pim kinase inhibitors
|
US20170107216A1
(en)
|
2015-10-19 |
2017-04-20 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
WO2017075377A1
(en)
|
2015-10-29 |
2017-05-04 |
Incyte Corporation |
Amorphous solid form of a bet protein inhibitor
|
MD3371190T2
(ro)
|
2015-11-06 |
2022-09-30 |
Incyte Corp |
Compuși heterociclici ca inhibitori PI3K-gamma
|
PL3377488T3
(pl)
|
2015-11-19 |
2022-12-19 |
Incyte Corporation |
Związki heterocykliczne jako immunomodulatory
|
US10045981B2
(en)
|
2015-11-24 |
2018-08-14 |
Jakpharm, Llc |
Selective kinase inhibitors
|
US20170174671A1
(en)
|
2015-12-17 |
2017-06-22 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
MD3394033T2
(ro)
|
2015-12-22 |
2021-04-30 |
Incyte Corp |
Compuși heterociclici ca imunomodulatori
|
EP3400221B1
(en)
|
2016-01-05 |
2020-08-26 |
Incyte Corporation |
Pyrazol / imidazol substituted pyridines as pi3k-gamma inhibitors
|
WO2017141104A2
(en)
|
2016-02-18 |
2017-08-24 |
Immune Therapeutics, Inc. |
Method for inducing a sustained immune response
|
EP4321513A2
(en)
|
2016-03-28 |
2024-02-14 |
Incyte Corporation |
Pyrrolotriazine compounds as tam inhibitors
|
CN109414410B
(zh)
|
2016-04-22 |
2022-08-12 |
因赛特公司 |
Lsd1抑制剂的制剂
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
US20170320875A1
(en)
|
2016-05-06 |
2017-11-09 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
WO2017205464A1
(en)
|
2016-05-26 |
2017-11-30 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
CN109715625B
(zh)
|
2016-06-20 |
2022-04-19 |
因赛特公司 |
Bet抑制剂的结晶固体形式
|
MY197280A
(en)
|
2016-06-20 |
2023-06-09 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
WO2017223414A1
(en)
|
2016-06-24 |
2017-12-28 |
Incyte Corporation |
HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
|
EP3484866B1
(en)
|
2016-07-14 |
2022-09-07 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
US20180055835A1
(en)
|
2016-08-25 |
2018-03-01 |
Immune Therapeutics Inc. |
Method for Treating And Preventing Protozoal Infections
|
WO2018044783A1
(en)
|
2016-08-29 |
2018-03-08 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
AR109595A1
(es)
|
2016-09-09 |
2018-12-26 |
Incyte Corp |
Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
|
US10280164B2
(en)
|
2016-09-09 |
2019-05-07 |
Incyte Corporation |
Pyrazolopyridone compounds and uses thereof
|
AU2017322427B2
(en)
|
2016-09-09 |
2021-12-23 |
Incyte Corporation |
Pyrazolopyridine derivatives as HPK1 modulators and uses thereof for the treatment of cancer
|
US20180072718A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
EP3558963B1
(en)
|
2016-12-22 |
2022-03-23 |
Incyte Corporation |
Bicyclic heteroaromatic compounds as immunomodulators
|
MD3558990T2
(ro)
|
2016-12-22 |
2023-02-28 |
Incyte Corp |
Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1
|
KR20190111025A
(ko)
|
2016-12-22 |
2019-10-01 |
인사이트 코포레이션 |
면역조절제로서의 벤조옥사졸 유도체
|
WO2018119263A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds derivatives as pd-l1 internalization inducers
|
WO2018119236A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Triazolo[1,5-a]pyridine derivatives as immunomodulators
|
ES2899402T3
(es)
|
2016-12-22 |
2022-03-11 |
Incyte Corp |
Derivados de piridina como inmunomoduladores
|
US20180228786A1
(en)
|
2017-02-15 |
2018-08-16 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
UA127183C2
(uk)
|
2017-06-29 |
2023-05-31 |
Рекордаті Індустріа Кіміка Е Фармацеутіка Спа |
ГЕТЕРОЦИКЛІЛМЕТИЛІДЕНОВІ ПОХІДНІ І ЇХ ЗАСТОСУВАННЯ ЯК МОДУЛЯТОРІВ РЕЦЕПТОРІВ mGluR5
|
US10722495B2
(en)
|
2017-09-08 |
2020-07-28 |
Incyte Corporation |
Cyanoindazole compounds and uses thereof
|
JP7447002B2
(ja)
|
2017-09-11 |
2024-03-11 |
クルーゾン・ファーマシューティカルズ・インコーポレイテッド |
SHP2のオクタヒドロシクロペンタ[c]ピロールのアロステリック阻害剤
|
SI3687996T1
(sl)
|
2017-09-27 |
2022-04-29 |
Incyte Corporation |
Soli pirolotriazinskih derivatov, ki so uporabne kot zaviralci TAM
|
MA50398B1
(fr)
|
2017-10-18 |
2021-10-29 |
Incyte Corp |
Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma
|
WO2019084459A1
(en)
|
2017-10-26 |
2019-05-02 |
Xynomic Pharmaceuticals, Inc. |
CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
MX2020005816A
(es)
*
|
2017-12-14 |
2020-08-20 |
SpecGx LLC |
Proceso de molienda de una etapa para preparar esteres de paliperidona micronizados.
|
US11306079B2
(en)
|
2017-12-21 |
2022-04-19 |
Incyte Corporation |
3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
|
KR20200120915A
(ko)
|
2018-01-26 |
2020-10-22 |
레코다티인더스트리아치미카이파마슈티카에스.피.에이. |
mGlu5 수용체의 조절제로서 트리아졸, 이미다졸 및 피롤 축합된 피페라진 유도체 및 이의 용도
|
DK3746429T3
(da)
|
2018-01-30 |
2022-05-02 |
Incyte Corp |
Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on)
|
MX2020008521A
(es)
|
2018-02-16 |
2020-12-03 |
Incyte Corp |
Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de trastornos relacionados con citocinas.
|
PL3755703T3
(pl)
|
2018-02-20 |
2022-11-07 |
Incyte Corporation |
Pochodne n-(fenylo)-2-(fenylo)pirymidyno-4-karboksyamidu i związki pokrewne jako inhibitory hpk1 do leczenia nowotworu
|
US10745388B2
(en)
|
2018-02-20 |
2020-08-18 |
Incyte Corporation |
Indazole compounds and uses thereof
|
WO2019164847A1
(en)
|
2018-02-20 |
2019-08-29 |
Incyte Corporation |
Indazole compounds and uses thereof
|
US20190292188A1
(en)
|
2018-02-27 |
2019-09-26 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
SG11202008560VA
(en)
|
2018-03-08 |
2020-10-29 |
Incyte Corp |
AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
|
UA127925C2
(uk)
|
2018-03-30 |
2024-02-14 |
Інсайт Корпорейшн |
Лікування гнійного гідраденіту з використанням інгібіторів jak
|
PE20211911A1
(es)
|
2018-03-30 |
2021-09-28 |
Incyte Corp |
Compuestos heterociclicos como inmunomoduladores
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
US11299473B2
(en)
|
2018-04-13 |
2022-04-12 |
Incyte Corporation |
Benzimidazole and indole compounds and uses thereof
|
BR112020022392A2
(pt)
|
2018-05-04 |
2021-02-02 |
Incyte Corporation |
formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
JOP20200288A1
(ar)
|
2018-05-11 |
2020-11-11 |
Incyte Corp |
مشتقات تترا هيدرو – إيميدازو[4، 5-c]بيريدين كمعدِّلات مناعية pd-l1
|
MX2020012376A
(es)
|
2018-05-18 |
2021-03-09 |
Incyte Corp |
Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
|
WO2019227007A1
(en)
|
2018-05-25 |
2019-11-28 |
Incyte Corporation |
Tricyclic heterocyclic compounds as sting activators
|
PE20211208A1
(es)
|
2018-06-01 |
2021-07-05 |
Incyte Corp |
Regimen de dosificacion para el tratamiento de trastornos relacionados con pi3k
|
EP3813800A1
(en)
|
2018-06-29 |
2021-05-05 |
Incyte Corporation |
Formulations of an axl/mer inhibitor
|
US11046658B2
(en)
|
2018-07-02 |
2021-06-29 |
Incyte Corporation |
Aminopyrazine derivatives as PI3K-γ inhibitors
|
AU2019297361A1
(en)
|
2018-07-05 |
2021-02-25 |
Incyte Corporation |
Fused pyrazine derivatives as A2A / A2B inhibitors
|
GB2575490A
(en)
|
2018-07-12 |
2020-01-15 |
Recordati Ind Chimica E Farmaceutica Spa |
P2X3 receptor antagonists
|
WO2020028565A1
(en)
|
2018-07-31 |
2020-02-06 |
Incyte Corporation |
Tricyclic heteraryl compounds as sting activators
|
US10875872B2
(en)
|
2018-07-31 |
2020-12-29 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
US10899755B2
(en)
|
2018-08-08 |
2021-01-26 |
Incyte Corporation |
Benzothiazole compounds and uses thereof
|
WO2020047198A1
(en)
|
2018-08-31 |
2020-03-05 |
Incyte Corporation |
Salts of an lsd1 inhibitor and processes for preparing the same
|
SG11202102224UA
(en)
|
2018-09-05 |
2021-04-29 |
Incyte Corp |
Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
|
MA53726A
(fr)
|
2018-09-25 |
2022-05-11 |
Incyte Corp |
Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
KR20210109522A
(ko)
|
2018-10-31 |
2021-09-06 |
인사이트 코포레이션 |
혈액 질환의 치료를 위한 병용 요법
|
WO2020102150A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
WO2020102198A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
WO2020102216A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Substituted heterocyclic derivatives as pi3k inhibitors
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
JP2022514089A
(ja)
|
2018-12-19 |
2022-02-09 |
インサイト・コーポレイション |
胃腸疾患の治療のためのjak1経路阻害剤
|
TW202039502A
(zh)
|
2018-12-20 |
2020-11-01 |
美商英塞特公司 |
咪唑并嗒嗪及咪唑并吡啶化合物及其用途
|
US20220056049A1
(en)
|
2019-01-07 |
2022-02-24 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
US11472791B2
(en)
|
2019-03-05 |
2022-10-18 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
AU2020232757A1
(en)
|
2019-03-05 |
2021-10-07 |
Incyte Corporation |
JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
WO2020223235A1
(en)
|
2019-04-29 |
2020-11-05 |
Incyte Corporation |
Mini-tablet dosage forms of ponatinib
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
CA3147918A1
(en)
|
2019-08-06 |
2021-02-11 |
Incyte Corporation |
Solid forms of an hpk1 inhibitor
|
BR112022001508A2
(pt)
|
2019-08-08 |
2022-07-12 |
Laekna Ltd |
Método de tratamento de câncer
|
AR119624A1
(es)
|
2019-08-09 |
2021-12-29 |
Incyte Corp |
Sales de un inhibidor de pd-1 / pd-l1
|
JP2023509260A
(ja)
|
2019-08-14 |
2023-03-08 |
インサイト・コーポレイション |
Cdk2阻害剤としてのイミダゾリルピリミジニルアミン化合物
|
JP2022545923A
(ja)
|
2019-08-26 |
2022-11-01 |
インサイト・コーポレイション |
A2a/a2b阻害剤としてのトリアゾロピリミジン
|
EP4037773A1
(en)
|
2019-09-30 |
2022-08-10 |
Incyte Corporation |
Pyrido[3,2-d]pyrimidine compounds as immunomodulators
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
CN115298177A
(zh)
|
2019-10-11 |
2022-11-04 |
因赛特公司 |
作为cdk2抑制剂的双环胺
|
CR20220169A
(es)
|
2019-10-14 |
2022-10-27 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores de fgfr
|
JP2023506118A
(ja)
|
2019-10-16 |
2023-02-15 |
インサイト・コーポレイション |
皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
KR20220101664A
(ko)
|
2019-11-11 |
2022-07-19 |
인사이트 코포레이션 |
Pd-1/pd-l1 억제제의 염 및 결정질 형태
|
WO2021113462A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Derivatives of an fgfr inhibitor
|
JP2023505258A
(ja)
|
2019-12-04 |
2023-02-08 |
インサイト・コーポレイション |
Fgfr阻害剤としての三環式複素環
|
CA3166549A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
|
KR20220125287A
(ko)
|
2020-01-10 |
2022-09-14 |
인사이트 코포레이션 |
Kras 억제제로서 트리사이클릭 화합물
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
US11530218B2
(en)
|
2020-01-20 |
2022-12-20 |
Incyte Corporation |
Spiro compounds as inhibitors of KRAS
|
WO2021158891A1
(en)
|
2020-02-06 |
2021-08-12 |
Incyte Corporation |
Salts and solid forms and processes of preparing a pi3k inhibitor
|
WO2021198962A1
(en)
|
2020-04-01 |
2021-10-07 |
Cytocom Inc. |
Method for treating viral diseases
|
IL297165A
(en)
|
2020-04-16 |
2022-12-01 |
Incyte Corp |
Soysag tricyclic CRS inhibitors
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
GB202008135D0
(en)
|
2020-05-29 |
2020-07-15 |
Neolife Int Llc |
Dietary supplements
|
KR20230027086A
(ko)
|
2020-06-02 |
2023-02-27 |
인사이트 코포레이션 |
Jak1 저해제의 제조 공정
|
KR20230031242A
(ko)
|
2020-06-03 |
2023-03-07 |
인사이트 코포레이션 |
골수증식성 신생물의 치료를 위한 병용 요법
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
MX2022015493A
(es)
|
2020-06-12 |
2023-03-21 |
Incyte Corp |
Compuestos de imidazopiridazina y usos de los mismos.
|
US11753413B2
(en)
|
2020-06-19 |
2023-09-12 |
Incyte Corporation |
Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
|
WO2021257857A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Naphthyridinone compounds as jak2 v617f inhibitors
|
US11767323B2
(en)
|
2020-07-02 |
2023-09-26 |
Incyte Corporation |
Tricyclic pyridone compounds as JAK2 V617F inhibitors
|
BR112023000047A2
(pt)
|
2020-07-02 |
2023-03-14 |
Incyte Corp |
Compostos de ureia tricíclicos como inibidores da v617f da jak2
|
US11661422B2
(en)
|
2020-08-27 |
2023-05-30 |
Incyte Corporation |
Tricyclic urea compounds as JAK2 V617F inhibitors
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
US11767320B2
(en)
|
2020-10-02 |
2023-09-26 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of KRAS
|
KR102271247B1
(ko)
*
|
2020-11-04 |
2021-06-30 |
삼천당제약주식회사 |
안과용 현탁액 조성물의 제조방법
|
PE20231438A1
(es)
|
2020-11-06 |
2023-09-14 |
Incyte Corp |
Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo
|
WO2022099075A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Crystalline form of a pd-1/pd-l1 inhibitor
|
US11780836B2
(en)
|
2020-11-06 |
2023-10-10 |
Incyte Corporation |
Process of preparing a PD-1/PD-L1 inhibitor
|
WO2022115120A1
(en)
|
2020-11-30 |
2022-06-02 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
TW202241436A
(zh)
|
2020-11-30 |
2022-11-01 |
美商英塞特公司 |
抗cd19抗體及帕薩昔布(parsaclisib)之組合療法
|
KR20230118118A
(ko)
|
2020-12-08 |
2023-08-10 |
인사이트 코포레이션 |
백반증의 치료를 위한 jak1 경로 저해제
|
WO2022133176A1
(en)
|
2020-12-18 |
2022-06-23 |
Incyte Corporation |
Oral formulation for a pd-l1 inhibitor
|
US11919908B2
(en)
|
2020-12-21 |
2024-03-05 |
Incyte Corporation |
Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
|
KR20230157940A
(ko)
|
2020-12-29 |
2023-11-17 |
인사이트 코포레이션 |
A2a/a2b 저해제, pd-1/pd-l1 저해제 및 항-cd73 항체를포함하는 병용 요법
|
EP4274578A1
(en)
|
2021-01-11 |
2023-11-15 |
Incyte Corporation |
Combination therapy comprising jak pathway inhibitor and rock inhibitor
|
US11958861B2
(en)
|
2021-02-25 |
2024-04-16 |
Incyte Corporation |
Spirocyclic lactams as JAK2 V617F inhibitors
|
GB202103100D0
(en)
|
2021-03-05 |
2021-04-21 |
Suda Pharmaceuticals Ltd |
Mitigating the off-target pharmacology of anagrelide in the treatment of thrombocytosis in various diseases
|
US20220306633A1
(en)
|
2021-03-22 |
2022-09-29 |
Incyte Corporation |
Imidazole and triazole kras inhibitors
|
CA3219495A1
(en)
|
2021-05-03 |
2022-11-10 |
Incyte Corporation |
Ruxolitinib for the treatment of prurigo nodularis
|
JP2024516302A
(ja)
|
2021-05-03 |
2024-04-12 |
インサイト・コーポレイション |
結節性痒疹を治療するためのjak1経路阻害薬
|
WO2022261160A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
AR126101A1
(es)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
Heterociclos tricíclicos como inhibidores de fgfr
|
KR20240016318A
(ko)
|
2021-07-02 |
2024-02-06 |
애슬레티스 바이오사이언스 코., 엘티디. |
Pd-l1 상호작용의 면역조절제로서의 헤테로사이클릭 화합물
|
WO2023283213A1
(en)
|
2021-07-07 |
2023-01-12 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
CA3224841A1
(en)
|
2021-07-14 |
2023-01-19 |
Zhenwu Li |
Tricyclic compounds as inhibitors of kras
|
WO2023019430A1
(en)
|
2021-08-17 |
2023-02-23 |
Ascletis Bioscience Co., Ltd. |
Compounds as immunomodulators of pd-l1 interactions
|
US20230174555A1
(en)
|
2021-08-31 |
2023-06-08 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
WO2023049697A1
(en)
|
2021-09-21 |
2023-03-30 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
CN113908932A
(zh)
*
|
2021-09-22 |
2022-01-11 |
浙江工业大学 |
一种磁性粉体连续细化及级分的方法与装置
|
WO2023056421A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
CA3235146A1
(en)
|
2021-10-14 |
2023-04-20 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
WO2023102184A1
(en)
|
2021-12-03 |
2023-06-08 |
Incyte Corporation |
Bicyclic amine compounds as cdk12 inhibitors
|
WO2023107705A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
WO2023122134A1
(en)
|
2021-12-22 |
2023-06-29 |
Incyte Corporation |
Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
|
CN114289159B
(zh)
*
|
2021-12-29 |
2023-06-06 |
湖北华世通生物医药科技有限公司 |
碳酸司维拉姆的后处理方法及其制备方法
|
WO2023172921A1
(en)
|
2022-03-07 |
2023-09-14 |
Incyte Corporation |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
WO2023174210A1
(en)
|
2022-03-14 |
2023-09-21 |
Laekna Limited |
Combination treatment for cancer
|
WO2023178285A1
(en)
|
2022-03-17 |
2023-09-21 |
Incyte Corporation |
Tricyclic urea compounds as jak2 v617f inhibitors
|
TW202402279A
(zh)
|
2022-06-08 |
2024-01-16 |
美商英塞特公司 |
作為dgk抑制劑之三環三唑并化合物
|
WO2023250430A1
(en)
|
2022-06-22 |
2023-12-28 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
WO2024030600A1
(en)
|
2022-08-05 |
2024-02-08 |
Incyte Corporation |
Treatment of urticaria using jak inhibitors
|